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Abstract
Immunodominance in T cell responses to complex antigens like viruses is still incompletely understood. Some data indicate
that the dominant responses to viruses are not necessarily the most protective, while other data imply that dominant
responses are the most important. The issue is of considerable importance to the rational design of vaccines, particularly
against variable escaping viruses like human immunodeficiency virus type 1 and hepatitis C virus. Here, we showed that
sequential inactivation of dominant epitopes up-ranks the remaining subdominant determinants. Importantly, we
demonstrated that subdominant epitopes can induce robust responses and protect against whole viruses if they are
allowed at least once in the vaccination regimen to locally or temporally dominate T cell induction. Therefore, refocusing T
cell immune responses away from highly variable determinants recognized during natural virus infection towards
subdominant, but conserved regions is possible and merits evaluation in humans.
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Introduction
In any one individual, CD4
+ and CD8
+ T cell responses
elicited by virus infection or vaccination focus on a relatively
small number of epitopes [1]. This immunodomination results
from an interplay of multiple factors, which on one hand
determine the abundance of displayed peptide-loaded MHC
determinants on the surface of APCs and, on the other hand,
affect the numbers of naı ¨ve T cells and their capacity to
efficiently compete for their cognate determinants and generate
effector and memory CD8
+ T cell populations [2–6]. A
consequence of immunodominance is that potentially protective
responses to a majority of virus-carried determinants might not
be used to their full potential or at all by the host immune
system.
This issue is particularly pertinent to the human immunodefi-
ciency virus type 1 (HIV-1). Given the huge quasi-speciation of
HIV-1 in human populations [7] and its rapid escape from the
dominant T cell responses in infected individuals [8–11], explo-
itation of subdominant T cell epitopes by vaccines might stimulate
T cell responses against HIV-1 that are more effective than those
that occur naturally. The first natural T cell responses to the first-
recognized immunodominant epitopes in HIV-1 infection almost
invariably lead to rapid selection of escape mutants, while more
effective responses to conserved epitopes only arise later [9].
The importance of subdominant epitopes in control of HIV-1
replication in vivo was also implied in a study, where HIV-1-
infected individuals with a stronger cytotoxic reactivity against
several subdominant epitopes had lower virus load than the
subjects lacking such activity, while the most immunodominant
response against the same epitope in either subjects was identical
[12]. Some virus and tumour mouse models have also shown that
CD8
+ T cells specific for subdominant epitopes can contribute to
the protective immunity [5,13–17]. Thus, better understanding of
the rules governing immunodominance may lead to novel ra-
tional strategies for induction of broader, more protective T cell
responses against HIV-1 and other viruses.
In preclinical evaluation of HIV vaccines, in the absence of
simple functional correlates of protection against HIV-1 [18],
various in vitro T cell parameters, such as IFN-c production, are
used to evaluate immune responses stimulated by candidate
vaccines. However, these assays may not measure the true
protective functions. Therefore, we established two surrogate virus
challenge models of mice in order to examine how vaccine-
stimulated T cell responses protected against a real virus infection
in vivo. These models employ a replication competent vaccinia
virus strain Western Reserve sharing with vaccines the HIV-1-
derived immunogen [19,20], and EcoHIV, which carries a gene
coding for envelope gp80 of ecotropic murine leukemia virus
in place of the HIV-1 envelope and therefore can efficiently
infect mouse cells through receptor called cationic amino acid
transporter type 1 [21–23]. In this report, we employ these two
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cells specific for subdominant HIV-1 CD8
+ T cell epitopes.
In the experiments reported here, we used the candidate HIV-
1 vaccine immunogen HIVA [24], mapped its CD8
+ Tc e l l
epitopes in BALB/c mice and determined their hierarchy
[25,26]. This allowed us to test, by removing more immunodo-
minant epitopes, whether or not cellular immune responses
focused on the subdominant determinants could be protective.
This question is very important for the HIV-1 vaccine
development, because, besides the problem of early virus escape
from T cell responses, the enormous variability of the infecting
virus could also be tackled by stimulating T cell responses against
subdominant epitopes [27] in the most invariant regions of the
HIV-1 proteome common to the major clades [28,29]. We
investigated this by removing dominant epitopes from the vaccine
and testing whether different vaccine vectors affect the pattern of
dominance. We also asked if vaccine administration into
anatomically separate sites partially overcomes epitope competi-
tion and increases the breadth of elicited CD8
+ T cell responses.
Finally, we assessed the protective efficacy of these up-ranked
CD8
+ T cell responses against virus challenges. The results
strongly support further development of the conserved region
vaccine strategy and its evaluation in humans.
Results
Mapping of CD8
+ T cell epitopes and their
immunodominance hierarchy
Our research interests lie in development of the T cell
component of HIV-1 vaccines stimulating protective CD8
+ T cell
responses. The first-generation T cell immunogen, designated
HIVA (Figure 1A) [24], has served as an extremely useful tool for
iterative improving of CD8
+ T cell induction by experimental
vaccines in mice, non-human primates and humans [reviewed in
[30]]. To increase the power of T cell analysis and study the role of
subdominant determinants, H-2
d class I-restricted epitopes
contained in the HIVA immunogen were mapped in detail. Thus,
the most immunodominant epitope of HIVA is RGPGRAFVTI
[Env residues 311–320 [31], by us historically designated H for
‘HIV’ [32]] restricted by H-2D
d and H-2L
d molecules [31,33].
The H epitope was attached to the C-terminus of HIVA to
facilitate quality control of clinical vaccine batches. The H-specific
response dominated CD8
+ T cell responses to other well defined
epitopes in HIVA such as H-2K
d-restricted AMQMLKDTI (Gag
residues 197–205, designated G1) and TTSTLQEQI (Gag
residues 239–247, designated G2) [34]. Particularly the G1
epitope was previously reported to be immunodominant in
BALB/c mice [26,35], but from HIVA induced hardly detectable
responses (Figure 1B and D top). Note that HIV-1 clade A in
epitope position 7 contains aspartate rather than glutamate, which
is a less immunogenic epitope variant [26]. Using 15-mer peptides
overlapping by 11 amino acids (15/11) across the whole HIVA
protein [36], a strong CD8
+ T cell response was detected to the
polyepitope region of HIVA in addition to epitope H, which was
subsequently narrowed to sequence IFQSSMTKI (Pol 258–266,
designated P; Figure 1C). This epitope is not processed from its
natural Pol context (E-JI, TH unpublished) due to an adjacent
proline immediately upstream of the epitope, which prevents
NH2-terminal trimming [37]; in that position, HIVA contains
alanine. To distinguish impaired G1 epitope processing from other
mechanisms of immunodominance, modified immunogen HI-
VAdH was constructed, from which epitope H was physically
removed (Figure 1A), and used to immunize BALB/c mice. While
the frequencies of IFN-c-producing CD8
+ cells responding to the
G1 peptide, and indeed to the P peptide, were noticeably, though
not significantly increased, responses to peptide G2 remained in
the ex vivo ICS assay undetectable (Figure 1D). Nevertheless, G2
responses were primed, because a specific IFN-c production was
detected in HIVAdH-immune splenocytes following a 5-d G2
peptide-driven culture expansion (Figure 1E) in an experimental
setting that is highly unlikely to support priming of naı ¨ve CD8
+ T
cells. Relative to the HIVA vaccination, increased in vivo lysis of
G1- and P-pulsed targets was also observed in HIVAdH
vaccinated mice (Figure 1F). Thus, this series of experiments
demonstrated that a single strong epitope can dominate CD8
+ T
response to vaccination and significantly narrow the specificity of
the total response.
Serial up-ranking of subdominant epitopes by
inactivation of dominant epitopes
Deletion of immunodominant epitope H had a limited impact
on restoring responses to epitopes G1 and G2. To further
investigate this phenomenon, we serially inactivated CD8
+ T cell
epitopes in the order of their immunodominance. To maintain the
HIVA protein integrity, epitopes P and G1 were mutated rather
than deleted by substituting the anchor amino acid residues
required for a strong binding to the H-2K
d molecule (Figure 2A).
The resulting double and triple mutants of the HIVA immunogen
were called dHmP and dHmPG1, respectively. Their comparable
intracellular expression levels and half-life were demonstrated
(Figure S1A), and the altered peptide sequences IFGSSMTKA
and AMEFLKDTA were confirmed to be unable to bind H-2K
d
in a T2 binding assay (Figure S2A). Groups of BALB/c mice were
immunized 2x using the modified HIVA immunogens vectored by
plasmid DNA and the immune responses were measured in IFN-c
ELISPOT, ICS and in vivo killing assays. First, it was confirmed by
the absence of IFN-c production that splenocytes from mice
immunized with mutated HIVA vaccines dHmP and dHmPG1
were unable to recognize the altered P and G1 peptides,
respectively (Figure 2A and B). Second, consistently in all three
assays, immune responses directed against subdominant epitopes
were serially recovered, however, not to the same extent. A
significant restoration of G1-specific T cell responses, now
comparable to those against H and restored P, was observed in
dHmP-immunized group, while immunization with dHmPG1
vaccine failed to restore the G2-specific response (Figure 2B and
C). Because the response to the G2 epitope remained undetectable
even in the dHmPG1-immunized mice, overlapping 15/11
peptides across the whole HIVA immunogen were used again to
search for another yet unidentified epitope of a higher rank.
Indeed, a response was detected and mapped to a 15-mer peptide
NPPIPVGDIYKRWIILGLNK (Figure 2D). This peptide contains
Author Summary
The body’s reaction to infections is dominated by strong
immune responses focused on a small number of protein
regions, while ignoring the other. These strong responses
may be protective against invariant viruses, but fail to
control viruses that can change quickly. In particular for
the AIDS virus, it happens that the few targeted regions
during natural infection are highly variable, and rapidly
change and become unrecognized by the mounted
responses, i.e. escape. Here, we demonstrated that even
the naturally under-recognized protein regions can induce
robust responses and confer protection against whole
viruses, and therefore should be made use of by
vaccination strategies.
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+ T helper epitope present in the Los
Alamos National Laboratory HIV Sequence Database, and
peptide NPPIPVGDI, designated NPP, was shown to be restricted
by H-2D
d and H-2L
d (Figure S2B). Thus, step-wise deletion of
immunodominant CD8
+ T cell epitopes restores responses to the
subdominant epitopes in the hierarchy.
Peptide-MHC affinity, T cell avidity and response kinetics
contribute to immunodominance
In the previous section, we established the hierarchy of T cell
responses against HIVA-derived epitopes 10 d after immunization
to be H.P..G1.NPP..G2. To characterize and compare the
corresponding peptides, we assessed the binding affinities of the H,
P, G1 and G2 peptides for their respective MHC class I using TAP-
deficient T2 cell lines stably transformed with H-2D
d, H-2K
d or H-
2L
d complexes and found that the peptide binding affinities directly
correlated with the immunodominance hierarchy (Figure 3A).
We also measured avidities of T cell responses recovered through
the sequential HIVA epitope up-ranking. First, responsiveness of
immune splenocytes following 3 plasmid DNA deliveries was
measured in an ICS assay upon re-stimulation with peptide
concentrations ranging from 10
28 to 10 mM for 5 h (Figure 3A).
Judging from the curve slopes and in vitro peptide concentrations
achieving maximum IFN-c
+CD107a/b
+CD8
+ cell frequencies, 10-
to 100-fold less H peptide for HIVA-induced responses was
necessary relative to the P peptide for the HIVAdH-induction
Figure 1. Enhancement of subdominant responses by deletion of immunodominant epitope. A) Schematic representation of the HIVA
and HIVAdH immunogens depicting the locations of the H-2
d-restricted CD8
+ T cell epitopes and deletion of epitope H. B) Immunogenicity of
pTHr.HIVA DNA. A group of 4 BALB/c mice were immunized with a single dose of 100 mg of pTHr.HIVA DNA. Ten d later, splenocytes were isolated
and assessed in an ex vivo IFN-c ELISPOT assay using the known G1 and H peptides. Responding cell frequencies are shown as mean6SD. C) Fine
mapping of a previously unidentified CD8
+ T cell epitope P. Groups of 4 BALB/c mice were primed with 50 mg of pTHr.HIVA DNA and boosted with
5610
6 PFU of MVA.HIVA 2 wk later. Two wk after the boost, splenocytes were assessed in an ICS assay for IFN-c production using 14-mer and 6
staggered overlapping 9-mer peptides. D) Immunogenicity of HIVA and HIVAdH immunogens. Mice were immunized with immunogens HIVA or
HIVAdH as described in C. Two wk after the boost, splenocytes were tested in an ICS assay for IFN-c production against the H, P, G1 and G2 epitopes.
Inserted numbers indicate IFN-c producing cells as a percentage of total CD8
+ splenocytes. E) G2-specific responses are detectable after culture
expansion. Splenocytes from immunized mice as in D were pooled and re-stimulated in vitro for 5 d with peptide G2 and assessed in an ICS assay for
the production of IFN-c upon G2 peptide restimuation. IFN-c-producing cells as percentages of total CD8
+ splenocytes are indicated. F) In vivo
recognition of subdominant epitopes. Mice were immunized as in D and the cytolytic activity was assessed in an in vivo lysis of syngeneic peptide-
pulsed cells in naı ¨ve and vaccinated animals. Representative examples are shown with inserted numbers indicating the percentages of peptide-
specific target killing. Results from one out of four individually immunized and tested animals are shown.
doi:10.1371/journal.ppat.1002041.g001
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PLoS Pathogens | www.plospathogens.org 3 May 2011 | Volume 7 | Issue 5 | e1002041Figure 2. Serial up-ranking of epitopes. A) Groups of 4 BALB/c mice were immunized 2x i.m. with 100 mg of DNA at a 2-wk interval. Two wk later,
splenocytes were assessed in an ELISPOT assay for production of IFN-c upon re-stimulation with peptides indicated above. Shown are schematic
diagrams of HIVA and the three modified immunogens with representative examples of the ELISPOT well images. B) Mice were immunized as in A
and 4 wk later, splenocytes were assessed in an ICS assay to measure CD8
+ T cells secreting IFN-c upon re-stimulation with peptide indicated in the
top left corner. Group means6SD are shown. C) Identical groups of mice were assessed for cytolytic activity in an in vivo lysis of syngeneic peptide-
pulsed cells transferred into naı ¨ve or vaccinated animals. Representative examples of dot plots are shown (top) and the peptide-specific lyses are
expressed as a group mean6SD (bottom). D) Groups of 3 BALB/c mice were immunized 3x with 100 mg of DNA indicated above the dot plot in 2-wk
intervals and the designated NPP peptide-specific responses were assessed by IFN-c ICS 2 wk later. The FACS plots are representative examples with
IFN-c producing cells as a percentage of CD8
+ splenocytes shown in the top right panels. All experiments were repeated at least once.
doi:10.1371/journal.ppat.1002041.g002
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PLoS Pathogens | www.plospathogens.org 4 May 2011 | Volume 7 | Issue 5 | e1002041Figure 3. Contributing mechanisms of immunodominance. A) Binding affinities of peptides H, P, G1 and G2 (as indicated in the top right
corners) to their respective MHC class I complexes stably transfected into TAP-deficient T2 cell lines were assessed. T2 cell lines were incubated with
decreasing peptide concentrations ranging from 100 mM to 0.1 mM indicated above the H peptide histogram and the cell surface peptide-loaded
MHC complexes were detected by fluorochrome-conjugated mAb (DB Biosciences) and quantified using FACS flow cytometer. B) and C) Groups of 3
BALB/c mice were given 3x immunizations using 100 mg of DNA expressing the index or mutated forms of HIVA at 3 wk intervals and their T cell
responses were analyzed 4 wk later. B) Splenocytes were assessed in an ICS assay using peptides indicated above the graphs at concentrations
ranging from 10 to 10
28 mM for 5 h. Cells were gated on IFN-c-producing CD8
+ T cell populations positive (top) or negative (bottom) for CD107a/b.
Note the different y-axis scales on the top and bottom graphs. C) The response kinetics of CD8
+ T cells re-stimulated with 0.1 mM peptides was
assessed in an ICS assay in 1-h intervals for a period of 4 h. Data shown are as mean6SD of [CD8
+CD107a/b
+IFN-c
+ cells at each time point (%)] 4
[CD8
+CD107a/b
+IFN-c
+ at 4 h (%)]. One out of two independent experiments is shown.
doi:10.1371/journal.ppat.1002041.g003
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the predominant binding of H peptide to H-2D
d, and P and G1
peptides to H-2K
d. For individual determinants when dominant,
the peak cell frequencies at 10 mM peptide concentration were
3.2%, 3.3%, 3.8% and 0.8% of total CD8
+ splenocytes for peptide
H in group HIVA, peptide P in group HIVAdH, peptide G1 in
group dHmP and peptide NPP in group dHmPG1, respectively.
Thus overall, epitopes H, P and G1 have similar intrinsic immuno-
fgenicities when not dominanted by stronger epitopes. In non-
degranulating IFN-c
+CD107a/b
2CD8
+ cells, only peptide H
induced low, but significant IFN-c response in 0.65% of total
CD8
+ cells following the HIVA vaccination (Figure 3B, bottom).
Finally, a constant 0.1 mM concentration of one of the four H,
P, G1 or NPP peptides was used to restimulate immune spleno-
cytes initially for 90 min as a pre-incubation period followed by
additional 1 to 4 h (Figure 3C) sufficient for the IFN-c expression
to reach maximum [38]. The time-course suggested a trend
whereby the more immunodominant epitopes reached their full
IFN-c/CD107a/b response faster (Figure 3C). Thus, peptide
affinity for MHC, T cell avidity and response kinetics are
mechanisms contributing to immunodomination of epitopes
within HIVA.
Spatial and/or temporal dominance is required for
efficient induction of subdominant responses
Next, we wanted to assess whether responses to subdominant
epitopes can be improved to the level of the dominant ones by
separating their induction either anatomically or in time from the
dominant determinants. Employing the HIVA and dHmP
constructs, mice were immunized using various regimens of mixed
or split injections depicted in Figure 4A. After a 23-wk rest, the
mice were briefly re-stimulated with vaccinia virus strain Western
Reserve WR.HIVA, sacrificed and their responses were analyzed
using a multicolour flow cytometry (Figure 4, also see Figure S3 for
representative dot plots). A number of observations were made.
Thus, responses to the G1 epitope were significantly increased
relative to those specific for epitopes H and P following both
HIVA-dHmP and dHmP-HIVA prime-boost regimens (Fig 4B,
groups 4 and 5). As for anatomical separation, split vaccine
administration for both priming and boosting yielded equivalent T
cell frequencies against all three epitopes (4B, groups 6 and 8),
while pre-mixed vaccines injected into 2 sites failed to induce anti-
G1 responses (Figure 4B, groups 7 and 9). Finally, physically
separated (Figure 4B, group 8), but not mixed (Figure 4B, group 9)
priming followed by HIVA only boosting also induced equal
responses to all three epitopes. Therefore, either temporal or
spatial separation of subdominant from dominant epitopes
increases the breadth of the T cell responses.
Epitope hierarchy is affected by vector regimen and can
change with time
Vaccine vectors can affect responses to the transgene product by
differential activation of innate immunity e.g. through pattern-
recognition receptors [39] and by generating CD8
+ T cell epitopes
derived from the vector, which can undesirably interfere or
compete with the induction of insert-specific responses [40,41]. To
investigate the influence of vector delivery on the hierarchy of
epitopes, groups of BALB/c mice were primed with pTH.HIVA
plasmid DNA and boosted with one of four vaccines: pTH.HIVA,
MVA.HIVA [24], Semliki Forest Virus replicons VREP.HIVA
[42], or a replication-competent vaccinia virus WR.HIVA [20].
Because long-term vaccine protection requires establishment of
T cell memory, responses to epitopes H, P, G1 and G2 were
measured 100 d after the last vaccination. The most striking
difference was observed between the DNA-DNA and the
heterologous regimens in that the DNA-DNA-induced H-specific
memory T cells no longer dominated the anti-HIVA response and
were replaced by T cells specific for peptide P (Figure 5A). This
change in the epitope hierarchy over time was confirmed in
separate experiments specifically comparing CD8
+ T cell respons-
es at 100 and 28 d post vaccination (Figure 5B).
Mutated HIVA vaccines partially protect against vaccinia
virus WR.HIVA challenge
Next, protective efficacy of the mutated HIVA immunogens was
assessed. Because mice cannot be challenged with HIV-1,
replicating vaccinia virus WR.HIVA was used as a surrogate
virus challenge. In this model, the WR.HIVA load in ovaries 5 d
after challenge serves as the infection quantitative readout [20].
Thus, BALB/c mice were vaccinated 3x with the intact or
mutated HIVA immunogens delivered by pTH plasmid DNA.
Nine wk after the last vaccination, analysis of the T cell memory
induced to the H, P, G1 and NPP determinants in circulating
PBMC were carried out prior to the challenge and confirmed
shifts in the response hierarchy induced by mutated HIVA
immunogens observed above including the loss of the H epitope
superiority at this late time point (Figure 6A). One week after the
bleed, mice where challenged with WR.HIVA. Consistent with the
immunogenicity data, the groups of mice that received the HIVA,
HIVAdH and dHmP immunogens showed a similar, approxi-
mately 1000-fold decrease in the virus load relative to the naı ¨ve
group, while the protection induced by dHmPG1 vaccine was
100-fold lower (Figure 6B). To assess the initial dominance of the
anti-H response, groups of BALB/c mice were also immunized
once with the DNA vaccines and challenged 10 d later. Indeed,
early after vaccination, the HIVA immunogen conferred the best
protection decreasing the WR.HIVA load by 6 orders of
magnitude (Figure 6C). Thus, together the early and late challenge
experiments indicated that subdominant epitopes contribute to the
protective efficacy and their contribution inversely correlates with
their position in the epitope hierarchy: for the HIVA immunogen
and WR.HIVA challenge, the stronger response they induce, the
bigger their protective role is. Their relative protective efficacy can
change with time.
G1 epitope alone protects against EcoHIV if not
dominated
Protective efficacy against chimaeric EcoHIV/NDK [21,22]
provided by the G1 epitope was assessed when generated from
several different immunogens. EcoHIV is particularly suitable for
the first, quick assessment of efficacy of T cell-inducing vaccines as it
doesnotexpresstheHIV-1Envand,therefore,doesnotcarrythe H
epitope, but contains the clade D version of G1 AMQMLKETI,
designated G1E (Figure 7A). Immunogen HIVB is a clade B near-
equivalent of HIVA [23], which also contains the G1E epitope, but
not the H epitope. In mice immunized twice with pTH.HIVB
DNA, both pre- and post-challenge ICS analysis indicated that the
G1 epitope generated the only detectable CD8
+ T cell response
(Figure 7B). These G1E-specific responses correlated with lower
EcoHIV/NDK load in splenocytes of challenged BALB/c mice
(p=0.001). Amino acid 7E-for-D substitution in the G1 epitope of
the HIVB vaccine decreased this protection (p=0.77) and the
epitopeknock-outabolishedcompletelyvaccineefficacy(Figure7C).
Inferior protection by the G1D epitope was also observed using the
HIVA mutant dHmP and our second-generation immunogen
HIVconsvdH [28] (Figure 7D). Finally, there was a trend indicating
Protection by Subdominant CD8
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tective responses than dHmP presumably because in HIVA, the
protective G1D epitope was dominated by irrelevant epitopes H
and P (Figure 7D). Thus, G1 when up-ranked as the most im-
munodominant vaccine epitope is sufficient to induce protective
efficacy; this protection may be compromized by irrelevant/non-
protective, but superior epitope.
Discussion
There is a very appealing rationale to focus vaccine-induced
HIV-1-specific CD8
+ T cell responses on invariant determinants
of the HIV-1 proteome [12,28,29,43]. In the work presented here,
we provide further experimental evidence in support of this
approach by demonstrating the protective potential of subdomi-
nant epitopes against two surrogate virus challenges. A number of
important observations have been made.
First, the pattern of CD8
+ T cell immunodominance can be
altered by modifying vaccine immunogens, therefore, immunodo-
mination is a relative relationship between epitopes rather than an
epitope’s absolute status. Although the shift in the immunodomi-
nance was demonstrated previously for a loss of a single epitope
[5,14,16,17,26,44], the extent to which this phenomenon applies
to other subdominant epitopes within the same protein immuno-
gen of a subunit vaccine has not been investigated. Here, we show
that sequential inactivation of three CD8
+ T cell epitopes on the
top of the immunodominance hierarchy leads to a gradual epitope
up-ranking reflected in increased magnitudes of the remaining
responses.
Second, subdominant epitopes have the potential to replace the
stronger ones on the top of the immunodominance hierarchy. This
is an important prerequisite for anti-HIV-1 vaccine strategies,
which aim to deal with the HIV-1 diversity and escape by
directing prophylactic CD8
+ T cell responses away from the
hypervariable regions recognized during primary HIV-1 infection
[9] to subdominant, but invariable parts of the HIV-1 proteome
[12,28,29,43]. Early focus on the HIV-1 functionally conserved
protein sequences, which cannot change without a likely high cost
to HIV-1 fitness [45,46], may provide host immune responses with
the critical extra edge in the chase of the ‘ever’-escaping HIV-1
during the primary infection [9,47–50] as well as offer a global
universal cross-clade vaccine [28].
Third, we demonstrated that epitope hierarchy can change with
time and this change may depend on the means of the immunogen
delivery. In the case presented here, the boosting vaccine vector
influenced the relative position of epitopes H and P in the order of
Figure 4. Physical separation of subdominant and dominant epitopes induces broad CD8
+ T cell responses. A) Groups of 5 BALB/c mice
were given 2x a total of 100 mg DNA at 4-wk intervals as indicated in with the HIVA or HIVAdH vaccines being given either mixed or separately into
the muscles of the left and right hind legs. After a 23-wk rest, the mice were briefly re-stimulated with recombinant vaccinia virus WR.HIVA delivered
i.p. and their H-, P- and G1-specific responses were analyzed using a multicolour flow cytometry 4 d later. B) Graphs show IFN-c-producing
CD8
+CD107a/b
+ cell frequencies following an in vitro peptide re-stimulation indicated below. C) The graph gives the total IFN-c production by
CD8
+CD107a/b
+ cells summing frequencies of G1-, P- and H-specific CD8
+ CD107a/b
+ cells. Results in B and C are shown as mean6SD. One out of at
two independent experiments is shown.
doi:10.1371/journal.ppat.1002041.g004
Protection by Subdominant CD8
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regimen, epitope H was the strongest at 28 d post vaccination, but,
by 100 d, was dominated by epitope P. This was not observed for
the other investigated boosting vaccine vectors and, thus, the
choice of a vaccine vector may have a profound effect on the
pattern of dominance within the transgene product. It remains
untested whether such hierarchy swap happens only after a single
pTH.HIVA DNA delivery. The mechanism for this phenomenon
is not known, but it is not likely caused by exhaustion of the H-
specific CD8
+ T cells. We published previously long-term
immunogenicity of one pTH.HIVA DNA delivery to BALB/c
mice and, although the read out involved only peptide H and not
peptide P, 182 days later 51617 SFU/10
6 of ex vivo H-specific
splenocytes were detected in an IFN-c ELISPOT assay, and
following an additional 5-day-in vitro re-stimulation with H
peptide, expanded effectors specifically lysed 25% of
51Cr-labeled
target cells. In the same experiment, 2x pTH.HIVA DNA induced
89639 SFU/10
6 and yielded similar levels of H-specific
51Cr
release. Thus these cells at least for these two effector functions
appeared normal [42]. Other studies investigated response
hierarchies to the whole viruses rater than a single protein. For
epitopes expressed from poxviruses, shaping of immunodomi-
nance during boost, but not prime, was attributed to cross-
competition of CD8
+ T cells [51]. Changes in epitope hierar-
chy were also reported for other viruses such as lymphocytic
choriomeningitis virus (LCMV), influenza virus and herpes
viruses and the suspected underlying mechanisms included
T cell exhaustion, kinetics of viral protein expression and
cross-presentation [4,52–54]. Change with time in epitope
hierarchy is well documented for responses to Epstein-Barr virus
(EBV) lytic and latent proteins (reviewed in [55]) and shapes the
immunodominance of anti-LCMV cytotoxic T cell responses [4].
In both EBV and LCMV infections, this phenomenon was
explained by the biology of the virus; in contrast, the H and P
epitopes are expressed from the same protein. For the HIVA
epitopes, the epitope hierarchy was mirrored by T cell avidity for
the MHC-peptide complexes and relative kinetics of individual
peptide-specific T cell responses. A degree of competition
depending on the affinity of responding T cells was also reported
for peptide-pulsed dendritic cells and was much more pronounced
for T cells with the same epitope specificity [56,57]. Thus, a
number of mechanisms determine the epitope ranking and their
relative importance is likely specific for each antigen and virus/
vaccine vector combination studied.
Fourth, generation of a broad CD8
+ T cell response is a major
goal of current vaccine strategies particularly against highly
variable infectious agents such as HIV-1 and various ways towards
achieving this are suggested in the literature. For example,
anatomic separation and heterologous prime-boost regimens
partially overcame epitope competition and generated co-
dominant responses against two [14] or a number of [29] unequal
epitopes derived from HIV-1. Using a string of five human
melanoma epitopes, immunodominance could be overcome by
boosting of DNA-primed responses using a mixture of recombi-
nant viruses, each encoding different antigenic determinants [58].
Our data suggest that either priming or boosting of responses to
Figure 5. Vector of the boost vaccine influences the epitope hierarchy. A) Groups of 3–4 BALB/c mice were primed with 100 mgo f
pTHr.HIVA DNA and boosted with the same dose of pTHr.HIVA DNA or 5610
6 PFU of MVA.HIVA, VREP.HIVA or WR.HIVA at a 2-wk interval. Hundred d
later, cytolytic activity was assessed in an in vivo lysis assay using syngeneic peptide-pulsed cells in naı ¨ve and vaccinated animals. B) Groups of 3
BALB/c mice received 2x 100 mg of pTHr.HIVA DNA 2 wk apart and assessed for the cytolytic activity at 100 (left) or 28 d (right) post-immunization.
The relative immunodominance of responses to individual epitopes was calculated as a percentage of the total CD8
+ cell response. Results are shown
as mean6SD. p values for the H and P epitope-specific response comparison are inserted above the columns. Panel B is a repetition of the important
observation from panel A. This is further confirmed in Figure 6A.
doi:10.1371/journal.ppat.1002041.g005
Protection by Subdominant CD8
+ T Cell Epitopes
PLoS Pathogens | www.plospathogens.org 8 May 2011 | Volume 7 | Issue 5 | e1002041subdominant epitopes can be used to increase the response
breadth as long as the weaker epitope is allowed to dominate at
least once locally or in time. Again, the subtle discrepancies with
some published results can be most likely reconciled by differences
in individual experimental and/or vaccine designs.
Finally, we demonstrated that subdominant up-ranked epitopes
can be protective in vivo against viral challenge if a protocol for
efficient T cell stimulation by these epitopes can be developed.
These results confirm and expand several previous observations
[5,13–17] and have implications for design of vaccines inducing
CD8
+ T cell responses in general. However, whether or not a full
protective potential of subdominant epitopes can be harnessed by
a rational vaccine design also depends on the efficiency of
processing and presentation of these subdominant determinants on
the surface of HIV-1-infected cells during natural infection. CD4
+
T cells, the main cells of HIV-1 replication, are not ‘professional
primers’ of CD8
+ T cells (although are likely to expand already
primed responses) and many, if not most, T cell responses in
natural HIV-1 infection must be initiated by cross-priming [59].
Therefore, detection of responses to subdominant epitopes me-
asured by recognition of peptide-pulsed targets does not guarantee
that HIV-1-infected cells express that epitope on their surface.
Although escape mutations do occur in conserved regions [60]
pointing to an efficient presentation/recognition of at least some
epitopes, escape in these regions is less frequent. Indeed, dif-
ferences between recognition of peptide-pulsed and HIV-1-
infected targets were previously reported [61–64] and will be the
focus of our clinical studies with HIVconsv. Here, we demon-
strated that subdominant HIVA epitopes contribute to in vivo
protection against surrogate WR.HIVA infection and responses to
a single subdominant epitope G1 (AMQ) in Gag led to an
enhanced clearance of EcoHIV/NDK infection. CD8
+ T cells
specific for a single epitope protected mice against e.g. Plasmodium
berghei and LCMV [65,66] and protection after removing
dominant epitopes was reported for an experimental infection of
rhesus macaques with simian immunodeficiency virus [67].
Without a clear definition of functional correlates of T cell
protection against HIV-1 in humans, protection against surrogate
Figure 6. Recovered subdominant epitopes contribute towards protection against vaccinia virus WR.HIVA challenge. A) Groups of 4
BALB/c mice were given 3x 100 mg of DNA expressing the original and deleted forms of the HIVA immunogen at 3-wk intervals. Nine wk later, animals
were bled, their PBMC pooled and their vaccine-induced CD8
+ T cell responses recognizing the H, P, G1 and NPP peptides were assessed by IFN-c ICS
assay. Dot plots are shown with inserted numbers indicating IFN-c producing cells as a percentage of total CD8
+ splenocytes. B) Ten wk after the last
vaccination, animals were challenged with 2610
7 PFU of WR.HIVA i.p., sacrificed 4 d later and the challenge virus titre in ovaries was determined.
C) Groups of 3 BALB/c mice were given 1x 100 mg of DNA and challenged with 2610
7 PFU of WR.HIVA after 10 d and sacrificed 4 d later for the
ovaries titre determination. Results in B and C are shown as mean6SD. Panel A is independently confirmed by Figure 5, and panels B and C show one
of two experiments.
doi:10.1371/journal.ppat.1002041.g006
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+ T cell responses confer protection against EcoHIV/NDK challenge. A) G1 epitope variants in the three
used immunogens and the challenge EcoHIV. B) Eight BALB/c mice received 2x 100 mg of DNA of the HIVB vaccine containing epitope G1E (black
bars), its G1D variant (dark grey bars) or knock-out versions (KO; light grey bars) and their HIVB-induced responses were determined before (n=3) or
after (n=5) challenge with EcoHIV/NDK delivered 5 d after the last vaccination. For ICS assay, 5 pools (P1–P5) of overlapping peptides 15/11 across
the whole HIVB protein and peptides G1E or G1D were used for re-stimulation as indicated below the graphs. Results are shown as mean6SD. C) The
3 vaccinated and 1 unvaccinated control groups of 5 mice were challenged with EcoHIV/NDK and the EcoHIV/NDK loads in splenocytes were
determined using qPCR. The horizontal bars indicate group mean of the genome copy number per 10
6 splenocytes. D) Mice were immunized as
above with plasmid DNA expressing four different immunogens HIVA, dHmP, HIVconsvdH or HIVB containing variants of the G1 epitope or left naı ¨ve
as indicated below the graphs and challenged with EcoHIV/NDK 5 d later. The EcoHIV/NDK load was determined in the splenocytes and peritoneal
macrophages using qPCR. Group means are indicated by horizontal bars.
doi:10.1371/journal.ppat.1002041.g007
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of vaccine-elicited responses to control real virus infection in vivo.I t
does remain that these challenge models serve more as
experimental tools for studying the workings of the immune
system rather than predictors of efficacy of candidate HIV-1
vaccines in humans.
Taken together, the findings reported in this paper provide an
important reassurance for vaccine strategies targeting pathogens’
subdominant determinants. By the same token, higher-ranked
non-protective determinants may over-compete and likely delay T
cell induction against potentially protective epitopes. For some
natural virus infections, such as by HIV-1, responses to the
conserved regions may come too late to win the race with the virus
[9].
Materials and Methods
Vaccine construction and preparation
Design, construction and preparation of HIVA, HIVB and
HIVconsv vaccines were described previously [23,24,28]. The
epitopes of HIVA (Im,) and HIVB (Hong, D.Phil Thesis,
University of Oxford, 2009) genes were deleted or serially mutated
using standard techniques of recombinant DNA technology.
Mice, immunizations, bleeding and preparation of
splenocytes
Groups of 5- to 6-wk-old female BALB/c mice were used.
Under general anaesthesia, mice were immunized i.m. with
indicated doses of plasmid DNA or 5610
6 PFU of recombinant
MVA (rMVA). Mice were bled using a superficial vein. On the day
of sacrifice, spleens and peritoneal macrophages were collected.
Splenocytes were isolated by pressing spleens individually through
a 70-mM nylon cell strainer (BD Falcon) using a 5-ml syringe
rubber plunger. Following the removal of red blood cells with
RBC Lysing Buffer Hybri-Max (Sigma), splenocytes were washed
and resuspended in R10 for ELISPOT and intracellular cytokine
staining (ICS) assays. For in vitro expansion of cells, splenocytes
were resuspended in Lymphocyte Medium [R-10 (RPMI 1640
supplemented with 10% FCS, penicillin/ streptomycin), 20 mM
HEPES and 15 mM 2-mercaptoethanol] and incubated for 5 d in
the presence of peptides or peptide pools (2 mg/ml).
Ethics statement
All animal procedures and care conformed strictly to the United
Kingdom Home Office Guidelines under The Animals (Scientific
Procedures) Act 1986. The protocol was approved by the local
Research Ethics Committee (Clinical Medicine, University of
Oxford). Experiments were carried out under Project Licence
no. 30/2406 held by TH with a strict implementation of the
Replacement, Reduction and Refinement (3Rs) principles.
Peptide synthesis
Individual peptides of 9- to 20-mer in length were synthesized in
an in-house facility using the Advanced Chemtech automated
synthesizer and yielded a purity of .95%. All peptides were
dissolved in DMSO (Sigma-Aldrich) to yield a stock of 10 mg/ml,
and stored at 280uC.
T2 peptide binding assay
TAP2 (Transporter Associated Protein 2)-deficient T2 cell lines
stably expressing D
d,K
d, and L
d molecules kindly provided by Dr.
Ted Hansen (Washington university, U.S.A.) were used to assess
the ability of MHCs to bind each peptide. In brief, 1610
5 cells
were incubated with 0/0.1/1.0/10/100 mM peptides in no-serum
RPMI (R-0) for 14 h at 37uC, 5% CO2 in a flat-bottomed 96-well
plate. 14 h later, cells were transferred to a round-bottomed 96-
well plate and washed with PBS before staining the cells with anti-
H-2K
d/H-2D
d-PE or anti-H-2L
d-PE (eBioscience) monoclonal
antibodies. Cells were then analyzed on a FACS flow cytometer.
In vivo killing assay
Naı ¨ve syngeneic mice were sacrificed, the splenocytes prepared
as above and the isolated splenocytes incubated with or without
peptides in R-10 at 37uC, 5% CO2 for 90 min and washed 3x.
Peptide-unpulsed target cells were labeled with CMTMR (Cell
Tracker Orange, Molecular Probes) only, while peptide-pulsed
target cells were labeled with CFSE (Molecular Probes) and
combined with or without CMTMR as described previously [25].
Differentially labeled cell cultures were washed, resuspended in
PBS and combined for intravenous adoptive transfer, with each
animal receiving approximately 26106 cells of each population.
After 12 h, animals were sacrificed, and their splenocytes were
isolated and analyzed using flow cytometry. Cytotoxicity was
calculated using the following formula: Adjusted % survival=100
x (% survival of peptide-pulsed cells/mean % survival of peptide
unpulsed cells), followed by the calculation of % specific lysis=100
- adjusted % survival [68].
Intracellular cytokine staining
ICS assay was performed as described previously [25] and
stored at 4uC until analysis. Anti-CD107a-FITC/anti-CD107b-
FITC (BD Biosciences), anti-CD16/32 (BD Biosciences) at 4uC for
30 minutes. All subsequent antibody stains were performed using
the same conditions. Cells were then washed and stained with anti-
CD8-PerCP/Pacific Blue, anti-CD4-APC-Cy7 (BD Biosciences),
anti-IFN-c-APC and anti-TNF-a-PE (BD Biosciences) mAbs were
used.
IFN-c ELISPOT assay
The ELISPOT assay was performed using the Mouse IFN-c
ELISpot kit (Mabtech) according to the manufacturer’s instruc-
tions. Spots were visualised using sequential applications of a
biotin-conjugated secondary anti-IFN-c mAb (R4-6A2, Rat IgG1),
an alkaline phosphatase and a chromogenic substrate (Bio-Rad)
and counted using the AID ELISpot Reader System (Autoimmun
Diagnostika).
Vaccinia virus WR.HIVA challenge/protection assay
Groups of BALB/c female mice naı ¨ve or immunized were
challenged with 2610
6 PFU of vaccinia virus WR.HIVA i.p. Four
d later, ovaries were collected and homogenized using MagNA
Lyser Green Beads (Roche) in a bead-based homogenizer.
Confluent Hu-TK
-143B cells in 6-well plates were infected in
duplicates with 10-fold serial dilutions of the homogenized ovaries.
Cells were stained with 0.1% crystal violet in 20% ethanol and the
numbers of plaques were counted.
FACS analysis
All chromogen-labeled cells were acquired using FACSCalibur
and CyAn ADP (Dako) flow cytometer and analyzed with
CellQuest software (BD Biosciences) and Flowjo (Tree Star),
respectively.
Preparation of EcoHIV/NDK stock and challenge
EcoHIV/NDK stocks were prepared as described previously
[22]. Briefly, plasmid DNA containing the infectious viral genome
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culture supernatant after two sequential 1-d incubations, concen-
trated by centrifugation and quantified by determination of the
Gag p24 content (Zeptometrix Corporation, Buffalo, NY) and
stored at 280uC until use. Mice were challenge with 2 mg p24 cell-
free virus by i.p. injection.
Quantitative real-time PCR (qPCR)
DNA from splenocytes and macrophages was isolated on the
day of euthanasia and qPCR was conducted using primers sense:
59-FTTAGCACTTGCTTGGGACGA, antisense: 59-TGTCCC-
AGAAGTTCCACART, Doubledye Taqman probe 59-TW-
GCACTTWTCTGGGACGA (F=G or C; R=A or G; W=A
or T) and ABI Prism 7700 instrument. Data are reported as
numbers of viral DNA copies per 10
6 of cells, cell numbers were
obtained by qPCR amplification of normalizing gene using gDNA
kit. Custom primers and probes detecting challenge virus DNA,
but not vaccines, and the house keeping gene were designed and
optimized by PrimerDesign (Southampton, UK).
Statistical analysis
The p values associated with an unpaired Student’s t-Test with a
two-tailed distribution were determined for differences between
both frequencies of vaccine-induced HIV-1-specific T cells and
EcoHIV/NDK genome copy numbers following challenge.
Supporting Information
Figure S1 Stability and expression of modified immunogens.
A) Stability of proteins HIVA (top) and dHmP (bottom) were
analysed using [35S]Methionine pulse-chase experiment. Briefly,
293T cells were incubated with [35S]Methionine for 16 h post
transfection and chased for 0, 2, 4, 8 and 24 h using unlabeled
medium. Cells were lysed and the recombinant proteins were
immunoprecipitated using anti-Pk antibody and separated on
SDS-PAGE. Following overnight exposure, bands were quantifies
using BioSpectrum Imaging System as depicted on the right.
B) Western blot analysis of 293T cells transiently transformed with
plasmid pTH expressing HIVB (lane 1), HIVB-G1D (lane 2),
HIVB-KO (lane 3) or empty pTH. Proteins in cell lysates were
separated using SDSPAGE and the recombinant proteins were
detected via the C-terminal Pk tag utilizing anti- Pk mAb and
HRP-conjugated protein A followed by ECL.
(PDF)
Figure S2 T2 assays for peptide binding affinity for MHC class
I. TAPdeficient T2 cell lines stably transformed with H-2Dd, H-
2Kd or H-2Ld complexes were kindly provided by Dr Hansen,
Washington University. Peptide-loaded MHC complexes were
detected by fluorochrome-conjugated mAb (DB Biosciences) and
the cells were analyzed using flow cytometer. A) Index and
mutated peptides P and G1 or B) peptide NNP as indicated above
the histograms as peptide-MHC were tested at decreasing
concentrations ranging from 100 mM to 0.01 mM (pink 100 mM,
turquoise 10 mM, orange 1 mM, green 0.1 mM, blue 0.01 mM and
grey filled no peptide) for binding to MHC class I complexes.
(PDF)
Figure S3 Spatial and temporal separation of dominant and
subdominant epitopes during vaccination (Additional data
for Figure 4). Groups of 4 BALB/c mice were given 2x a total
of 100 mg DNA at 4-wk intervals as indicated in Figure 4B with
the HIVA or HIVAdH vaccines being given either mixed or
separately into the muscles of the left and right hind legs. After a
23-wk rest, the mice were briefly re-stimulated with recombinant
vaccinia virus WR.HIVA delivered i.p. and their H, P and G1-
specific responses were analyzed using a multicolour flow
cytometry 4 d later. Representative examples are shown from
one mouse of each group.
(PDF)
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